Prosecution Insights
Last updated: August 15, 2026

Rani Therapeutics LLC

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
4
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (80%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (40%)
Double-patenting only1 (20%)
Double-patenting + other2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
60% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
40% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CARTER, SANDRA DILLAHUNT 1 56.1% +29.7%
D' AMBROSIO, THEA 1 55.8% +56.5%
IGEL JR, MARK ALAN 1 66.5% +28.7%
WITTLIFF, KATERINA ANNA 1 35.0% +18.8%
LEE, JIA-HAI 1 49.8% +48.0%

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17709245 SELF-SIZING DEVICE FOR DELIVERING A FORMULATION TO A LUMEN WALL WITTLIFF, KATERINA ANNA 32d overdue
18481893 THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE CARTER, SANDRA DILLAHUNT
18452358 TREATMENTS FOR HEMOPHILIA A D' AMBROSIO, THEA
17863806 SWALLOWABLE DEVICES FOR DRUG DELIVERY IN AN INTESTINAL TRACT IGEL JR, MARK ALAN
17515284 CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE LEE, JIA-HAI

Top Art Units

Art UnitApps
3783 2
1674 1
1654 1
1658 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18481893 THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE CARTER, SANDRA DILLAHUNT 1674 DPOther Non-Final OA Pending Oct 05, 2023
18452358 TREATMENTS FOR HEMOPHILIA A D' AMBROSIO, THEA 1654 DP Non-Final OA Pending Aug 18, 2023
17863806 SWALLOWABLE DEVICES FOR DRUG DELIVERY IN AN INTESTINAL TRACT IGEL JR, MARK ALAN 3783 §103 Final Rejection Pending Jul 13, 2022
17709245 SELF-SIZING DEVICE FOR DELIVERING A FORMULATION TO A LUMEN WALL WITTLIFF, KATERINA ANNA 3783 §103 Non-Final OA 32d overdue Pending Mar 30, 2022
17515284 CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE LEE, JIA-HAI 1658 §103DP Non-Final OA Pending Oct 29, 2021

Managing Rani Therapeutics LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month